The pig as an amplifying host for new and emerging zoonotic viruses

McLean, Rebecca K.; Graham, Simon P.

doi:10.1016/j.onehlt.2022.100384

Cited by 31 publications

(37 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expansion and intensification of pig, cattle, and poultry productions have resulted in significant changes to traditional husbandry practices leading to an environment conducive to increased emergence and spread of infectious diseases. These include several zoonotic viruses, including avian influenza, Japanese encephalitis, Nipah and coronaviruses, and others (McLean and Graham, 2022;Rathore et al, 2022;Thomas et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Odio¹,

Pérez²,

Batista-Duharte³

et al. 2022

J Pharm Pharmacogn Res

View full text Add to dashboard Cite

Context: The new generation of immunoenhancers will have to offer solutions to each clinical and technological limitation that currently exists. This innovative context requires periodic technological surveillance by the veterinary biopharmaceutical industry to anticipate technological changes and predict future competitive advantages. Aims: To evaluate the current status, scientific trends, and technological projections in the use of veterinary immunological adjuvants for productive and companion species in the period 2015 and 2021. Methods: The bibliometric analysis included scientific articles on adjuvants in veterinary medicine published in English in 2015–2021 and indexed on the Scopus and Web of Science platforms. All relevant records retrieved between 2015 and 2022 were grouped using the EndNote bibliographic manager, while the analysis of the relational metric indicator was performed and viewed by VOSviewer®. Instead, data on the main commercial veterinary vaccine adjuvants in 2022 were collected from the official websites of 20 veterinary vaccine manufacturers with experience in the market. Results: The academy dedicated 68.2% of its production to disseminating articles with original experimental results with 73.6% being novel notifications about adjuvants of natural, microbial and nanotechnological origin. Industrial production mainly used monoadjuvation (86.9%), inorganic salts adjuvants (48.1%), particularly aluminum hydroxide (43.0%), and classical technology (89.2%) to produce their commercial formulations. Ruminants, swines, and poultry dominated both sectors, with ruminants being the main protagonist. Conclusions: The new scientific knowledge will not have a significant impact on the veterinary pharmaceutical industry in the short term and the hegemonic continuity of traditional adjuvants, in particular aluminum hydroxide, is expected.

show abstract

Section: Discussionmentioning

confidence: 99%

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Odio¹,

Pérez²,

Batista-Duharte³

et al. 2022

J Pharm Pharmacogn Res

View full text Add to dashboard Cite

show abstract

“…These waterbirds harbor 16 HA and 9 NA genes subtypes, and usually experience clinically asymptomatic infections. Importantly, since more sequencing efforts have been implemented during the last years, mammals, such as swine, are emerging as key IAV reservoirs (Parrish et al, 2015;McLean and Graham, 2022). Recently, the phylogenetic diversity of IAV has increased with the identification of H17N10 and H18N11 subtypes of IAV in fruit bats (Zhu et al, 2012;Zhu et al, 2013;Yang et al, 2021).…”

Section: Introduction Influenza a Virusmentioning

confidence: 99%

“…In fact, this process is highly important to understand IAV evolution, ecology, and adaptation to new hosts, because new viruses can, among others, obtain advantages in viral replication, transmission, or the ability to evade host immune responses (Parrish et al, 2015;Lowen, 2017;Lowen, 2018;Wille and Holmes, 2019). In addition, antigenic drift has been described to be responsible for the emergence of novel IAV variants, when mutations in the viral genome are introduced and selected in the viral population (Shaw, 2007;Parrish et al, 2015;Short et al, 2015;Sutton, 2018;Wille and Holmes, 2019;McLean and Graham, 2022).…”

Section: Introduction Influenza a Virusmentioning

confidence: 99%

“…Moreover, IAV diversity and complexity highlight the relevance of the one-health approach to study IAV infections and spread, with the goal to reduce the impact of influenza disease on healthcare systems, animal welfare or food production (e.g., poultry industry) (Cox et al, 2009;Dorratoltaj et al, 2017;Mancera Gracia et al, 2020;Oladunni et al, 2021;Salvesen and Whitelaw, 2021). In addition, due to IAV infections across so many different animal species, there are continuous and transient spillover infections, which occasionally can result in sustained epidemic transmission (Short et al, 2015;Wille and Holmes, 2019;Wang et al, 2021;McLean and Graham, 2022). Stable transmission in new hosts depends on IAV and host ecology as well as the acquisition of specific genetic changes in the viral genome that allow productive infections.…”

Section: Introduction Influenza a Virusmentioning

confidence: 99%

“…Stable transmission in new hosts depends on IAV and host ecology as well as the acquisition of specific genetic changes in the viral genome that allow productive infections. Because of that, most of IAV host-jumping events are not successful (Shaw, 2007;Parrish et al, 2015;Short et al, 2015;Rajao et al, 2018;Sutton, 2018;Wille and Holmes, 2019;Oladunni et al, 2021;Verhagen et al, 2021;McLean and Graham, 2022;Murakami et al, 2022).…”

Section: Introduction Influenza a Virusmentioning

confidence: 99%

See 2 more Smart Citations

Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use

Nogales

DeDiego

Martínez-Sobrido

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Influenza A viruses (IAV) spread rapidly and can infect a broad range of avian or mammalian species, having a tremendous impact in human and animal health and the global economy. IAV have evolved to develop efficient mechanisms to counteract innate immune responses, the first host mechanism that restricts IAV infection and replication. One key player in this fight against host-induced innate immune responses is the IAV non-structural 1 (NS1) protein that modulates antiviral responses and virus pathogenicity during infection. In the last decades, the implementation of reverse genetics approaches has allowed to modify the viral genome to design recombinant IAV, providing researchers a powerful platform to develop effective vaccine strategies. Among them, different levels of truncation or deletion of the NS1 protein of multiple IAV strains has resulted in attenuated viruses able to induce robust innate and adaptive immune responses, and high levels of protection against wild-type (WT) forms of IAV in multiple animal species and humans. Moreover, this strategy allows the development of novel assays to distinguish between vaccinated and/or infected animals, also known as Differentiating Infected from Vaccinated Animals (DIVA) strategy. In this review, we briefly discuss the potential of NS1 deficient or truncated IAV as safe, immunogenic and protective live-attenuated influenza vaccines (LAIV) to prevent disease caused by this important animal and human pathogen.

show abstract

Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: greater similarity between humans and chickens than pigs

Kim,

Park,

Moon

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

The pig as an amplifying host for new and emerging zoonotic viruses

Cited by 31 publications

References 95 publications

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use

Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: greater similarity between humans and chickens than pigs

Contact Info

Product

Resources

About